The current price of SLS is $7.88 — it has decreased by 13.79% since the previous close. Data as of Nov 5, 2026.
SLS is down 18.17% over the past week, down 30.51% over the past month and up 386.42% over the past year. The price is below its 200-day moving average of $8.64.
Analysts' average 12-month price target for SLS is $35.00, which implies 344.16% upside from the current price. Individual estimates range from $35.00 to $35.00.
Of the 2 analysts covering SELLAS Life Sciences Group, Inc., 1 rates it a strong buy and 1 rates it a buy. The overall consensus is bullish. Analyst ratings are opinions and do not guarantee future performance.
SELLAS Life Sciences Group, Inc. has a market capitalization of $1.59B. The company belongs to the Healthcare sector. Compare it with other companies in the stock screener.
In its most recent quarterly report, SELLAS Life Sciences Group, Inc. posted a loss of $0.05 per share against an estimate of -$0.045, missing expectations by 11.11%. Upcoming reports are listed in the earnings calendar.
SELLAS Life Sciences Group, Inc. has not paid any dividends over the past year.
Companies most comparable to SELLAS Life Sciences Group, Inc. include Incyte Corporation, IDEAYA Biosciences, Inc., Immunome, Inc., Nurix Therapeutics, Inc. and ArriVent BioPharma, Inc.
In the latest trading session SLS moved between $7.83 and $9.05, a range of 15.48% of its current price.
Investing in stocks requires thorough research: study the company's financials, related news and technical analysis before making a decision. Technical analysis of SELLAS Life Sciences Group, Inc. shows a strong sell rating today and a sell rating on the weekly timeframe. Market conditions change quickly, so it is worth looking further ahead as well — the 1-month rating for SELLAS Life Sciences Group, Inc. is sell. Technical ratings are indicators, not investment advice.
Over the past 52 weeks SLS has traded between $1.39 and $15.88. The current price is 50.38% below its 52-week high.
Figures as of Nov 5, 2026. This information is provided for general purposes only and is not investment advice.